Loading data for OCS — first visit, this takes a few seconds.
Oculis Holding AG (OCS)
NasdaqGM: OCS
· Real-Time Price · USD
12.21
-0.22 (-1.77%)
At close: Aug 28, 2026, 8:00 PM
12.21
+0.00%
After-hours: 7:30 PM
The price, the headline numbers and the latest news, in one place.
Oculis Holding AG (OCS) Stock Price, Analysis & Data
-1.77% (1D)
No data available
| Bid | 8.8 |
| Market Cap | 678M |
| Revenue (ttm) | 1.17M |
| Net Income (ttm) | -79.19M |
| 0.23 | |
| -1.71 | |
| n/a | |
| -5.96 | |
| P/B (ttm) | 2.76 |
| P/S (ttm) | 578.00 |
| Earnings Date | Nov 5, 2026 |
| Ask | 15.29 |
| Volume | 221,869 |
| Avg. Volume (20D) | 585,204 |
| Open | 12.38 |
| Previous Close | 12.43 |
| Day's Range | 12.14 - 12.47 |
| 52-Week Range | 10.52 - 34.48 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About OCS
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the trea...
Industry Biotechnology
Sector Healthcare
IPO Date May 18, 2021
Employees 60
Stock Exchange NasdaqGM
Ticker Symbol OCS
Website https://oculis.com
Financial Performance
In 2025, Oculis's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -98.96M, an increase of 15.37%.
Financial StatementsEarnings Surprise
Oculis has released their quarterly earnings on Aug 6, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.16 exceeds estimates by 0.22, with 67.35% YoY growth.
Oculis Holding AG is scheduled to release its earnings on Nov 5, 2026, during market hours.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2